Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/28936
Title: From Postoperative to Preoperative: A Case Series of Hypofractionated and Single-Fraction Neoadjuvant Stereotactic Radiosurgery for Brain Metastases.
Austin Authors: Udovicich, Cristian;Ng, Sweet Ping ;Tange, Damien;Bailey, Nola;Haghighi, Neda
Affiliation: Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia..
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia..
Olivia Newton-John Cancer Wellness and Research Centre
Department of Neurosurgery, Peter MacCallum Cancer Centre, Melbourne, Australia..
Icon Cancer Centre, Epworth Hospital, Richmond, Australia..
Radiation Oncology
Issue Date: 1-Apr-2022
Publication information: Operative Neurosurgery (Hagerstown, Md.) 2022; 22(4): 208-214
Abstract: Postoperative stereotactic radiosurgery after resection of brain metastases is currently the standard of care. However, rates of leptomeningeal disease (LMD) after postoperative stereotactic radiosurgery have been reported to be >30%. Neoadjuvant stereotactic radiosurgery (NaSRS) has been proposed as an alternative treatment approach to decrease this risk. To report the local control (LC) and LMD rates in patients undergoing NaSRS. Our retrospective multicenter case series included consecutive patients planned for SRS followed by resection of intracranial lesions with a confirmed primary malignancy. Concurrent SRS alone to other intracranial lesions was permitted. Exclusion criteria included previous local treatment to that particular lesion and Eastern Cooperative Oncology Group performance status ≥3. Outcomes reported included LC, distant intracranial control (DC), overall survival, LMD, and radionecrosis (RN) rates. Overall, 28 patients with 29 lesions were eligible for analysis. The median follow-up was 12.8 months. The mean age was 62.5 (range 43-80) years, and 55% were Eastern Cooperative Oncology Group performance status 0 to 1. The most common primary malignancies included non-small cell lung cancer (43%) and melanoma (32%). Hypofractionated SRS was used in 62.1%. The 12-month LC and LMD rates were 91.3% and 4.0%, respectively. The 12-month RN, DC, and overall survival rates were 5.0%, 51.5%, and 60.1%, respectively. Compared with postoperative SRS, our study suggests that NaSRS leads to comparable local control with a decreased risk of LMD and RN. This is the first NaSRS series with a majority of patients treated with fractionated SRS. NaSRS is a promising approach for appropriate patients where surgical resection is a component of local therapy.
URI: https://ahro.austin.org.au/austinjspui/handle/1/28936
DOI: 10.1227/ONS.0000000000000101
ORCID: 0000-0001-6093-5164
0000-0003-1721-0680
Journal: Operative neurosurgery (Hagerstown, Md.)
PubMed URL: 35234410
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/35234410/
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

30
checked on Nov 2, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.